

Eleftheria Hatzimichael

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4506355/publications.pdf>

Version: 2024-02-01

147
papers

3,904
citations

126858

33
h-index

138417

58
g-index

149
all docs

149
docs citations

149
times ranked

7398
citing authors

#	ARTICLE	IF	CITATIONS
1	Leishmaniasis mimicking multiple myeloma. International Journal of Laboratory Hematology, 2022, 44, 44-46.	0.7	2
2	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. In Vivo, 2022, 36, 1302-1315.	0.6	2
3	Autophagy and cellular senescence in classical Hodgkin lymphoma. Pathology Research and Practice, 2022, 236, 153964.	1.0	4
4	Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Diseases (Basel, Switzerland), 2022, 10, 33.	1.0	4
5	A Novel β^0 -Thalassemia Deletion Associated with Severe Anemia at Birth and a β^+ -Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. Hemoglobin, 2021, 45, 351-354.	0.4	3
6	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. Leukemia Research, 2021, 100, 106479.	0.4	3
7	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. British Journal of Haematology, 2021, 192, 978-987.	1.2	4
8	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. Leukemia, 2021, 35, 1745-1750.	3.3	15
9	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. Blood Cancer Journal, 2021, 11, 30.	2.8	2
10	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Annals of Hematology, 2021, 100, 2279-2292.	0.8	10
11	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematological Oncology, 2021, 39, 336-348.	0.8	25
12	Novel Therapeutic Advances in β^+ -Thalassemia. Biology, 2021, 10, 546.	1.3	19
13	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist, 2021, 26, 597-609.	1.9	15
14	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. Leukemia Research, 2021, 107, 106595.	0.4	3
15	CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. Pathology Research and Practice, 2021, 225, 153567.	1.0	11
16	Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature. In Vivo, 2021, 35, 1951-1957.	0.6	2
17	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). Blood, 2021, 138, 1535-1535.	0.6	3
18	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.2	5
20	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	0.5	5
21	Hyponatremia in Patients with Hematologic Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 3721.	1.0	10
22	The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. <i>Annals of Nuclear Medicine</i> , 2020, 34, 707-717.	1.2	9
23	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	9
24	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	0.8	3
25	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	0.4	2
26	Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, Publish Ahead of Print, e1140-e1144.	0.3	1
27	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	1.3	6
28	Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	0.6	12
29	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	0.6	0
30	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	0.6	0
31	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	0.6	1
32	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	2.0	10
33	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
34	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018, 97, 1671-1682.	0.8	17
35	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.4	0
36	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematological Oncology, 2018, 36, 645-650.	0.8	6
38	Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry. Blood, 2018, 132, 3107-3107.	0.6	0
39	Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group. Blood, 2018, 132, 1822-1822.	0.6	0
40	Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. Journal of Clinical Lipidology, 2017, 11, 1095-1100.	0.6	23
41	SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. Tumor Biology, 2017, 39, 101042831769117.	0.8	5
42	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Letters, 2017, 400, 243-251.	3.2	26
43	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. European Journal of Haematology, 2017, 99, 409-414.	1.1	37
44	Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. Clinical and Experimental Medicine, 2017, 17, 291-304.	1.9	45
45	Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. Advances in Hematology, 2017, 2017, 1-7.	0.6	9
46	Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. Case Reports in Hematology, 2017, 2017, 1-5.	0.3	8
47	2017 Clinical trials update in new treatments of β^0 -thalassemia. American Journal of Hematology, 2016, 91, 1135-1145.	2.0	52
48	Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. Molecular and Clinical Oncology, 2016, 5, 23-26.	0.4	4
49	Megaloblastic anemia presenting with skin hyperpigmentation. International Journal of Hematology, 2016, 103, 479-480.	0.7	1
50	Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study. Blood, 2016, 128, 5476-5476.	0.6	0
51	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. Blood, 2016, 128, 2004-2004.	0.6	0
52	Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus "copositive lymphoproliferations. Human Pathology, 2015, 46, 1566-1571.	1.1	25
53	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	3.3	376
54	Abstract 3997: Expression profiling of a panel of apoptosis-associated microRNAs in acute myeloid leukemia identifies differentially expressed microRNAs that target epigenetic modifiers. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Expression Profiling of a Panel of Apoptosis Related Micrnas in Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4971-4971.	0.6	2
56	Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. Blood, 2015, 126, 5192-5192.	0.6	0
57	Profile of pacritinib and its potential in the treatment of hematologic disorders. Journal of Blood Medicine, 2014, 5, 143.	0.7	21
58	How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. Expert Review of Molecular Diagnostics, 2014, 14, 639-642.	1.5	3
59	Polycomb group proteins and MYC: the cancer connection. Cellular and Molecular Life Sciences, 2014, 71, 257-269.	2.4	51
60	“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of Hematology, 2014, 93, 129-139.	0.8	38
61	The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biology Direct, 2014, 9, 3.	1.9	77
62	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia, 2014, 28, 2075-2079.	3.3	57
63	Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic Activity. ACS Chemical Biology, 2014, 9, 2737-2741.	1.6	57
64	DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist. Cellular and Molecular Life Sciences, 2014, 71, 4421-4430.	2.4	28
65	Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 451-455.	0.2	5
66	A blood test to identify when melanoma metastasizes: a reality for melanoma management?. Melanoma Management, 2014, 1, 11-14.	0.1	0
67	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113.	0.6	3
68	Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI Journal, 2014, 13, 954-76.	0.5	6
69	Non-coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome. International Journal of Cancer, 2013, 133, 267-274.	2.3	81
70	Clinical trial design in biosimilar drug development. Investigational New Drugs, 2013, 31, 479-487.	1.2	41
71	The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cellular and Molecular Life Sciences, 2013, 70, 795-814.	2.4	246
72	Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. Journal of Investigative Dermatology, 2013, 133, 1278-1285.	0.3	44

#	ARTICLE	IF	CITATIONS
73	Revisiting bleomycin from pathophysiology to safe clinical use. Critical Reviews in Oncology/Hematology, 2013, 87, 90-100.	2.0	86
74	Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia. British Journal of Haematology, 2013, 163, 142-144.	1.2	3
75	Cancer Epigenetics: New Therapies and New Challenges. Journal of Drug Delivery, 2013, 2013, 1-9.	2.5	66
76	Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death and Disease, 2013, 4, e458-e458.	2.7	133
77	Metronomic chemotherapy beyond misconceptions. Haematologica, 2013, 98, e145-e145.	1.7	3
78	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. Blood, 2013, 122, 1867-1867.	0.6	1
79	Towards a Reference Human Platelet Transcriptome: Evaluation Of Inter-Individual Correlations and Its Relationship With a Platelet Proteome. Blood, 2013, 122, 2297-2297.	0.6	0
80	Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy. Blood, 2013, 122, 4084-4084.	0.6	0
81	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. Blood, 2013, 122, 1866-1866.	0.6	0
82	Decoding The BH3-Mimetic Pro-Apoptotic Activity Of Quercetin In Jurkat Cells. Blood, 2013, 122, 1672-1672.	0.6	0
83	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. American Journal of Blood Research, 2013, 3, 29-51.	0.6	36
84	Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. American Journal of Blood Research, 2013, 3, 181-5.	0.6	1
85	NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. British Journal of Cancer, 2012, 106, 1446-1452.	2.9	76
86	Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death and Disease, 2012, 3, e342-e342.	2.7	107
87	Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leukemia and Lymphoma, 2012, 53, 1709-1713.	0.6	13
88	NT5E CpG island methylation is a favourable breast cancer biomarker. British Journal of Cancer, 2012, 107, 75-83.	2.9	36
89	The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. British Journal of Cancer, 2012, 107, 1423-1432.	2.9	17
90	Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Supportive Care in Cancer, 2012, 20, 1353-1360.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal of Haematology, 2012, 89, 10-15.	1.1	28
92	Beyond mRNAs and Mirnas: Unraveling the Full-Spectrum of the Normal Human Platelet Transcriptome Through Next-Generation Sequencing. Blood, 2012, 120, 3298-3298.	0.6	3
93	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer. Oncotarget, 2012, 3, 78-83.	0.8	30
94	Abstract 4550: NT5E promoter methylation is a favorable breast cancer epigenetic biomarker. , 2012, , .		0
95	Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma.. Journal of Clinical Oncology, 2012, 30, e18567-e18567.	0.8	1
96	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. Blood, 2012, 120, 948-948.	0.6	0
97	Leptin and Adiponectin Blood Levels in Patients with Steady State Sickle Cell Disease Are Related to Chronic Hemolytic and Inflammatory Biomarkers. Blood, 2012, 120, 1012-1012.	0.6	1
98	Tissue Factor Pathway Inhibitor 2 (TFPI2) Is Commonly Methylated in Multiple Myeloma. Blood, 2012, 120, 4617-4617.	0.6	0
99	1037 POSTER The Prolyl-3-hydroxylases (P3H) and P3H-related Genes CRTAP and SC65 Are Novel Transcriptionally Silenced Genes in Burkitt's Lymphoma. European Journal of Cancer, 2011, 47, S107.	1.3	0
100	Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Annals of Hematology, 2011, 90, 1037-1045.	0.8	37
101	MEG3 imprinted gene contribution in tumorigenesis. International Journal of Cancer, 2011, 129, 773-779.	2.3	244
102	Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches. Molecules, 2011, 16, 4408-4427.	1.7	20
103	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. Cancer Research, 2011, 71, 3317-3327.	0.4	56
104	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. Blood, 2011, 118, 5083-5083.	0.6	4
105	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. Blood, 2011, 118, 5084-5084.	0.6	5
106	Methylation Status of the Collagen Prolyl-3 Hydroxylases (C-P3H) and C-P4H Genes in Multiple Myeloma: P3H2 Is Selectively Methylated. Blood, 2011, 118, 4639-4639.	0.6	0
107	Epigenetic Inactivation Targets the Arginine Biosynthetic Pathway At Two Levels in Multiple Myeloma. Blood, 2011, 118, 4640-4640.	0.6	0
108	Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica, 2010, 95, 406-414.	1.7	48

#	ARTICLE	IF	CITATIONS
109	The prolyl-4-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. European Journal of Haematology, 2010, 84, 47-51.	1.1	43
110	CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leukemia Research, 2010, 34, 148-153.	0.4	150
111	DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. British Journal of Cancer, 2010, 103, 265-274.	2.9	25
112	Hematopoietic stem cell transplantation. Stem Cells and Cloning: Advances and Applications, 2010, 3, 105.	2.3	76
113	Serum Adipocytokine and Vascular Inflammation Marker Levels in Beta-Thalassaemia Major Patients. Acta Haematologica, 2010, 124, 191-196.	0.7	18
114	Cytokine and Adhesion Molecule Expression Evolves Between the Neutrophilic and Lymphocytic Phases of Viral Meningitis. Journal of Interferon and Cytokine Research, 2010, 30, 661-665.	0.5	5
115	Study of specific genetic and epigenetic variables in multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2270-2274.	0.6	27
116	The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Annals of Oncology, 2009, 20, 775-779.	0.6	144
117	P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes. Leukemia Research, 2009, 33, S73-S74.	0.4	0
118	P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group. Leukemia Research, 2009, 33, S125.	0.4	0
119	Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leukemia Research, 2009, 33, 1272-1275.	0.4	12
120	von Hippel-Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease. Clinical Lymphoma and Myeloma, 2009, 9, 239-242.	1.4	32
121	Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia, 2008, 22, 1293-1295.	3.3	8
122	The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. British Journal of Haematology, 2008, 141, 557-558.	1.2	8
123	Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 171-175.	1.4	88
124	Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology, 2007, 12, 481-486.	0.7	18
125	Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient. Leukemia Research, 2007, 31, 119-120.	0.4	5
126	Epigenetic Profiling Identifies EGLN3 as a Frequent Target for Transcriptional Silencing in Plasma Cell Neoplasias.. Blood, 2007, 110, 2132-2132.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. International Journal of Laboratory Hematology, 2006, 28, 416-418.	0.2	19
128	Host Pharmacogenetics in the Treatment of HIV and Cancer. Current Drug Safety, 2006, 1, 107-116.	0.3	2
129	The genomics of new drugs in sickle cell disease. Pharmacogenomics, 2006, 7, 909-917.	0.6	4
130	The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. Annals of Oncology, 2006, 17, 503-506.	0.6	16
131	C-Reactive Protein and Vascular Cell Adhesion Molecule-1 as Markers of Severity in Sickle Cell Disease. Archives of Internal Medicine, 2006, 166, 366.	4.3	20
132	Serum levels of soluble interleukin-2 receptor alpha (sIL-2R α) as a predictor of outcome in brucellosis. Journal of Infection, 2005, 51, 206-210.	1.7	36
133	Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British Journal of Haematology, 2005, 130, 709-715.	1.2	116
134	Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Multiple Sclerosis Journal, 2005, 11, 272-275.	1.4	70
135	The Rationale and Development of New Drugs to Treat HIV Infection. Medicinal Chemistry, 2005, 1, 635-642.	0.7	5
136	Treatment of β^2 -Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules. Acta Haematologica, 2004, 111, 189-195.	0.7	22
137	Recombinant human erythropoietin therapy in a transfusion-dependent β^2 -thalassemia major patient. Annals of Hematology, 2001, 80, 492-495.	0.8	14
138	Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia. European Journal of Haematology, 2001, 66, 1-6.	1.1	40
139	Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. European Journal of Haematology, 2001, 66, 31-36.	1.1	7
140	Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. European Journal of Haematology, 2001, 67, 51-53.	1.1	28
141	Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. European Journal of Haematology, 2000, 64, 350-351.	1.1	3
142	The role of cytokines in sickle cell disease. Annals of Hematology, 2000, 79, 407-413.	0.8	87
143	Alpha-2-Macroglobulin and Interleukin-6 Levels in Steady-State Sickle Cell Disease Patients. Acta Haematologica, 2000, 104, 164-168.	0.7	24
144	A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival. Acta Haematologica, 1999, 101, 202-205.	0.7	8

#	ARTICLE	IF	CITATIONS
145	Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia. European Journal of Internal Medicine, 1999, 10, 27-31.	1.0	1
146	Serum beta α 2 μ microglobulin, TNF α and interleukins in myeloproliferative disorders. European Journal of Haematology, 1999, 63, 19-25.	1.1	17
147	Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. European Medical Journal (Chelmsford, England), 0, , .	3.0	0